î
îŒ
î
Pharvaris NV
PHVSî¹
詳现ãã£ãŒãã衚瀺
28.380USD
+0.660+2.38%
çµå€Â 11/28, 13:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
1.84Bæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
Intraday
1m
30m
1h
D
W
M
D
æ¬æ¥
+2.38%
5æ¥é
+14.30%
1ã¶æ
+28.53%
6ã¶æ
+69.74%
幎åæ¥
+48.04%
1幎é
+29.59%
詳现ãã£ãŒãã衚瀺
TradingKeyã®Pharvaris NVã®æ ªåŒã¹ã³ã¢î
é貚: USD æŽæ°æå»: 2025-10-27äž»èŠã€ã³ãµã€ã
å瀟ã®æ ªäŸ¡ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸãããŸããæ©é¢æè³å®¶ã«ããèªç¥åºŠã¯éåžžã«é«ãã§ããéå»30æ¥éã§ãè€æ°ã®ã¢ããªã¹ããå瀟ãè²·ããšè©äŸ¡ããŸãããæ ªäŸ¡ã¯æ¯æç·ãšæµæç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
Pharvaris NVã®ã¹ã³ã¢î°î°
æ¯æç·ãšæµæç·
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ã¬ãŒããŒãã£ãŒã
çŸåš
ååå€
ã¢ããªã¹ãç®æšæ ªäŸ¡
12
人ã®ã¢ããªã¹ãäºæ³ã«åºã¥ã
è²·ã
çŸåšã®è©äŸ¡
37.083
ç®æšæ ªäŸ¡
+30.67%
äžæäœå°
å
責äºé
ïŒã¢ããªã¹ãã®ã¬ãŒãã£ã³ã°ããã³ç®æšæ ªäŸ¡ã¯ãæ
å ±æäŸã®ã¿ãç®çãšããŠLSEG Data & AnalyticsãæäŸãããã®ã§ãããæè³å©èšãæ§æãããã®ã§ã¯ãããŸããã
Pharvaris NVã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
é«ãå©çæé·
å瀟ã®çŽå©çã¯æ¥çããªãŒãããŠãããææ°ã®å¹ŽéçŽå©çã¯USD 0.00ã§ãã
å²å®
å瀟ã®ææ°ã®PEã¯-9.76ã§ãéå»3幎éã®æ°Žæºãšæ¯èŒããŠå®å€åã«ãããŸãã
æ©é¢æè³å®¶ã®å£²ãè¶ã
ææ°ã®æ©é¢æè³å®¶ã®ä¿ææ ªæ°ã¯48.75Mæ ªã§ãåååææ¯ã§3.62%æžå°ããŠããŸãã
ã¢ã³ãã¬ã¢ã¹ã»ãã«ãã«ã»ã³ãä¿æ
ã¹ã¿ãŒæè³å®¶ã¢ã³ãã¬ã¢ã¹ã»ãã«ãã«ã»ã³ã¯æ¬éæã3.65Mæ ªä¿æããŠããŸãã
Pharvaris NV ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
財åææšî
EPS
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Pharvaris NVã®äŒæ¥æ å ±î
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
äŒæ¥ã³ãŒãPHVS
äŒæ¥åPharvaris NV
æé«çµå¶è²¬ä»»è
ãCEOãMr. Berndt Modig, CPA
ãŠã§ããµã€ãhttps://pharvaris.com/
ãããã質å
Pharvaris NVïŒPHVSïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îPharvaris NVïŒPHVSïŒã®çŸåšã®æ ªäŸ¡ã¯28.380ã§ãã
Pharvaris NVã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îPharvaris NVã®ãã£ãã«ãŒã·ã³ãã«ã¯PHVSã§ãã
Pharvaris NVã®52é±é«å€ã¯ãããã§ããïŒ
îPharvaris NVã®52é±é«å€ã¯28.480ã§ãã
Pharvaris NVã®52é±å®å€ã¯ãããã§ããïŒ
îPharvaris NVã®52é±å®å€ã¯11.510ã§ãã
Pharvaris NVã®æ䟡ç·é¡ã¯ãããã§ããïŒ
îPharvaris NVã®æ䟡ç·é¡ã¯1.84Bã§ãã
Pharvaris NVã®çŽå©çã¯ãããã§ããïŒ
îPharvaris NVã®çŽå©çã¯-100.88Mã§ãã
Pharvaris NV (PHVS) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãPharvaris NVïŒPHVSïŒã®ç·åè©äŸ¡ã¯è²·ãã§ãç®æšæ ªäŸ¡ã¯37.083ã§ãã
Pharvaris NV (PHVS) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îPharvaris NVïŒPHVSïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-2.338ã§ãã
é¢é£éèåå
-2.68%
-0.31%
+0.07%
-0.63%
+0.21%
-0.08%
+0.26%
+1.23%
-1.29%
0.00%
-0.30%
+0.33%
-0.26%
-0.13%
-0.39%
+0.15%
-0.53%
0.00%
+1.37%
+0.41%人æ°éæ
